Subscribe
Prostate cancer
androgen deprivation therapy for prostate cancer
Androgen deprivation therapy for prostate cancer includes surgical castration, which can quickly and continuously reduce levels to very low levels. The second is medical castration, which involves the use of analogs of luteinizing hormone-releasing hormone. Currently available products include leuprolide, goserelin, and triptorelin. Third, estrogen therapy, with diethylstilbestrol being the most common estrogen treatment. Surgical castration, medical castration, or estrogen therapy offer similar progression-free survival rates in patients with tumor-related outcomes.
Commonly used drugs for endocrine treatment of prostate cancer
The purpose of endocrine therapy for prostate cancer is to reduce the concentration of androgens in the body, inhibit the synthesis of androgens originating from the adrenal glands, inhibit the conversion of testosterone to dihydrotestosterone, or block the binding of androgens to their receptors, thereby inhibiting or controlling the growth of prostate cancer cells. The medications include a luteinizing hormone-releasing hormone analogue, with representative drugs being leuprorelin, goserelin, and triptorelin. There is also an androgen-blocking drug, including steroidal drugs with representative drugs like cyproterone acetate, and non-steroidal drugs with representative drugs like bicalutamide and flutamide. Additionally, there are estrogens, with the most common being diethylstilbestrol.